Brokerages Expect Eagle Pharmaceuticals Inc (EGRX) Will Announce Earnings of $1.08 Per Share

Share on StockTwits

Equities analysts forecast that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will announce $1.08 earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $1.12 and the lowest estimate coming in at $1.03. Eagle Pharmaceuticals reported earnings per share of $1.22 in the same quarter last year, which would indicate a negative year-over-year growth rate of 11.5%. The business is scheduled to announce its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year earnings of $3.94 per share for the current fiscal year, with EPS estimates ranging from $3.88 to $4.01. For the next fiscal year, analysts anticipate that the business will report earnings of $4.30 per share, with EPS estimates ranging from $4.17 to $4.43. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that follow Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.15. Eagle Pharmaceuticals had a return on equity of 19.71% and a net margin of 13.81%. The firm had revenue of $59.30 million for the quarter, compared to analysts’ expectations of $51.78 million.

EGRX has been the topic of a number of analyst reports. Cantor Fitzgerald set a $80.00 price objective on Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 3rd. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $94.00 price objective on the stock in a research note on Wednesday, July 11th. TheStreet lowered Eagle Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Tuesday, September 25th. Piper Jaffray Companies set a $86.00 price objective on Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, July 24th. Finally, Royal Bank of Canada set a $84.00 price objective on Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $86.50.

Shares of NASDAQ:EGRX traded down $1.54 during midday trading on Thursday, reaching $59.49. 122,200 shares of the company traded hands, compared to its average volume of 233,967. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.09 and a current ratio of 4.22. Eagle Pharmaceuticals has a 12 month low of $49.14 and a 12 month high of $85.66. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of 17.65 and a beta of 1.32.

Several large investors have recently added to or reduced their stakes in EGRX. State Board of Administration of Florida Retirement System increased its stake in Eagle Pharmaceuticals by 46.7% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 7,785 shares of the specialty pharmaceutical company’s stock worth $589,000 after acquiring an additional 2,480 shares during the last quarter. Swiss National Bank increased its stake in Eagle Pharmaceuticals by 45.8% in the 2nd quarter. Swiss National Bank now owns 20,700 shares of the specialty pharmaceutical company’s stock worth $1,566,000 after acquiring an additional 6,500 shares during the last quarter. Chartwell Investment Partners LLC bought a new position in Eagle Pharmaceuticals in the 2nd quarter worth about $12,063,000. New York State Common Retirement Fund increased its stake in Eagle Pharmaceuticals by 3.6% in the 1st quarter. New York State Common Retirement Fund now owns 64,467 shares of the specialty pharmaceutical company’s stock worth $3,397,000 after acquiring an additional 2,234 shares during the last quarter. Finally, Campbell Newman Asset Management Inc. increased its stake in Eagle Pharmaceuticals by 97.5% in the 2nd quarter. Campbell Newman Asset Management Inc. now owns 7,808 shares of the specialty pharmaceutical company’s stock worth $591,000 after acquiring an additional 3,854 shares during the last quarter.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Recommended Story: What is a Tariff?

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply